UK Markets close in 5 hrs 21 mins

Sesen Bio, Inc. (SESN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3893-0.0017 (-0.43%)
At close: 04:00PM EDT
0.3987 +0.01 (+2.41%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3910
Bid0.3800 x 1200
Ask0.3988 x 1200
Day's range0.3800 - 0.3970
52-week range0.3650 - 1.4700
Avg. volume1,992,631
Market cap77.651M
Beta (5Y monthly)0.65
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Sesen Bio and Carisma Therapeutics Announce Merger Agreement

    CAMBRIDGE, Mass. & PHILADELPHIA, September 21, 2022--Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered

  • Business Wire

    Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update

    CAMBRIDGE, Mass., August 08, 2022--Sesen Bio (Nasdaq: SESN) today reported operating results for the second quarter ended June 30, 2022. During the quarter, the Company paused clinical development of its lead asset, Vicineum™ for the treatment of non-muscle invasive bladder cancer (NMIBC), and turned its primary focus to the assessment of potential strategic alternatives with the goal of maximizing shareholder value, which it believes will be complete by the end of 2022.

  • Business Wire

    Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US

    CAMBRIDGE, Mass., July 18, 2022--Sesen Bio (Nasdaq: SESN) today announced that it has made the strategic decision to voluntarily pause further development in the US of its lead asset, Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of non-muscle invasive bladder cancer (NMIBC), following recent discussions with the US Food & Drug Administrat